Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD

Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD

Background & Aims: Glucagon-like peptide 1 receptor agonist (GLP-1RA) therapies deliver histological benefit in people with metabolic dysfunction-associated steatotic liver disease (MASLD). Multiple mechanisms may be important including weight loss, improved glycaemic control and putative di...

Full description

Saved in:
Bibliographic Details
Main Authors: Ahmad Moolla, Toryn Poolman, Nantia Othonos, Jiawen Dong, Kieran Smith, Thomas Cornfield, Sarah White, David W. Ray, Sofia Mouchti, Ferenc E. Mózes, Helena Thomaides-Brears, Stefan Neubauer, Jeremy F. Cobbold, Leanne Hodson, Jeremy W. Tomlinson
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:JHEP Reports
Subjects:
MASLD
GLP-1
Liraglutide
Weight loss
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555925000400
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items